Business Context and Reporting Period
Ocular Therapeutix, Inc. (OCUL) filed a Form 8-K on July 22, 2021, to provide a business update regarding its preliminary operational and financial results for the second quarter ended June 30, 2021. The company is an emerging growth company incorporated in Delaware, primarily deriving revenue from the sale of DEXTENZA (dexamethasone ophthalmic insert) and ReSure Sealant in the United States.
Key Financial Metrics
The filing provides preliminary, unaudited revenue estimates for the second quarter of 2021. Detailed metrics for profit, cash flow, margins, debt, and liquidity are not provided in this specific filing.
- Expected Total Net Product Revenue (Q2 2021): Approximately $11.7 million.
- Revenue by Product (Q2 2021): $11.1 million from DEXTENZA and $0.6 million from ReSure Sealant.
- In-Market Unit Sales (Q2 2021): Estimated 24,990 billable inserts.
- Monthly Unit Sales Breakdown: 8,025 (April), 7,186 (May), and 9,779 (June).
Material Changes Versus Prior Periods
The company reported significant growth in net product revenue compared to prior quarters:
- vs. Q1 2021: Revenue increased from approximately $7.3 million to $11.7 million.
- vs. Q2 2020: Revenue increased from approximately $1.6 million to $11.7 million.
Guidance, Outlook, and Risks
The figures disclosed are based on preliminary and unaudited information and management's estimates as of the filing date. The company is still finalizing its operational and financial results for the quarter. The independent registered public accounting firm has not audited or reviewed these figures, and they are subject to completion of customary closing procedures. No specific forward-looking guidance beyond these preliminary estimates is provided in this text.
Investor Verification Checklist
- Verify the final audited revenue figures in the upcoming Form 10-Q for the quarter ended June 30, 2021.
- Confirm the final in-market unit sales count once closing procedures are complete.
- Review the full text of the press release (Exhibit 99.1) for additional context on the business update.
- Monitor subsequent filings for data on gross margins, operating expenses, and cash flow, which are absent from this 8-K.